Story perspectives

FDA Approves New Antibiotics to Combat Gonorrhea Resistance

12/16/2025

47 5

Summary

Story summary

The U.S. Food and Drug Administration (FDA) approves two antibiotics, zoliflodacin and gepotidacin, to treat gonorrhea.
Zoliflodacin is a single-dose oral medication, while gepotidacin, previously approved for urinary tract infections, is now authorized for gonorrhea.
Health experts say the approvals address urgent antibiotic resistance in gonorrhea, with nearly 600,000 U.S. cases reported last year.
Infectious disease specialists view these approvals as a significant advancement in combating this challenging infection.

1 of 1

Story summary

The U.S. Food and Drug Administration (FDA) approves two antibiotics, zoliflodacin and gepotidacin, to treat gonorrhea.
Zoliflodacin is a single-dose oral medication, while gepotidacin, previously approved for urinary tract infections, is now authorized for gonorrhea.
Health experts say the approvals address urgent antibiotic resistance in gonorrhea, with nearly 600,000 U.S. cases reported last year.
Infectious disease specialists view these approvals as a significant advancement in combating this challenging infection.